Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IBRXNASDAQ:IMVTNASDAQ:TALSNASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$2.53-5.6%$2.63$1.83▼$7.63$2.23B0.335.57 million shs6.25 million shsIMVTImmunovant$14.46-0.7%$15.46$12.72▼$34.47$2.46B0.751.22 million shs754,314 shsTALSTalaris Therapeutics$15.32+0.3%$18.84$0.89▼$27.95$655.14M2.18386,531 shs140,319 shsVCELVericel$40.92-1.1%$42.09$37.39▼$63.00$2.06B1.31408,745 shs300,720 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio-5.60%-10.92%-5.95%-26.02%-63.54%IMVTImmunovant-0.69%0.00%+0.07%-31.98%-51.08%TALSTalaris Therapeutics+1.06%-1.61%-11.84%+25.06%+8.84%VCELVericel-1.11%-3.67%+2.17%-21.31%-18.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIBRXImmunityBio1.8323 of 5 stars3.61.00.00.01.91.70.6IMVTImmunovant2.7004 of 5 stars4.51.00.00.03.61.70.0TALSTalaris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVCELVericel2.668 of 5 stars3.51.00.00.03.50.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBRXImmunityBio 3.20Buy$12.25384.19% UpsideIMVTImmunovant 2.90Moderate Buy$38.33165.10% UpsideTALSTalaris Therapeutics 0.00N/AN/AN/AVCELVericel 3.00Buy$61.1449.42% UpsideCurrent Analyst Ratings BreakdownLatest TALS, IBRX, IMVT, and VCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.005/20/2025IBRXImmunityBioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$4.25 ➝ $5.005/12/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.005/12/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/5/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/28/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/23/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.004/16/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/15/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.004/11/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$61.00 ➝ $51.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBRXImmunityBio$31.22M71.52N/AN/A($0.88) per share-2.88IMVTImmunovantN/AN/AN/AN/A$2.08 per shareN/ATALSTalaris TherapeuticsN/AN/AN/AN/A$4.33 per shareN/AVCELVericel$238.54M8.64$0.01 per share3,081.95$4.73 per share8.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBRXImmunityBio-$583.20M-$0.58N/AN/AN/A-8,016.83%N/A-110.02%8/11/2025 (Estimated)IMVTImmunovant-$259.34M-$2.62N/AN/AN/AN/A-77.94%-69.82%6/4/2025 (Estimated)TALSTalaris Therapeutics-$73.89M-$1.79N/A∞N/AN/A-39.93%-37.37%N/AVCELVericel-$3.18M$0.03682.1193.00N/A1.56%1.48%0.96%8/7/2025 (Estimated)Latest TALS, IBRX, IMVT, and VCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/4/2025Q4 2025IMVTImmunovant-$0.72N/AN/AN/AN/AN/A5/12/2025Q1 2025IBRXImmunityBio-$0.12-$0.15-$0.03-$0.15$17.50 million$16.52 million5/8/2025Q1 2025VCELVericel-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million3/3/2025Q4 2024IBRXImmunityBio-$0.26-$0.15+$0.11-$0.09$8.74 million$7.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIBRXImmunityBioN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ATALSTalaris TherapeuticsN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBRXImmunityBioN/A2.682.64IMVTImmunovantN/A6.046.04TALSTalaris TherapeuticsN/A15.4115.41VCELVericelN/A4.614.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBRXImmunityBio8.58%IMVTImmunovant47.08%TALSTalaris Therapeutics67.61%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipIBRXImmunityBio76.79%IMVTImmunovant5.90%TALSTalaris Therapeutics16.50%VCELVericel5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBRXImmunityBio590882.62 million115.67 millionOptionableIMVTImmunovant120169.86 million159.84 millionOptionableTALSTalaris Therapeutics8442.76 million35.71 millionNot OptionableVCELVericel30050.34 million46.79 millionOptionableTALS, IBRX, IMVT, and VCEL HeadlinesRecent News About These CompaniesVericel's (VCEL) Overweight Rating Reiterated at StephensMay 24 at 9:42 AM | marketbeat.comVericel Co. (NASDAQ:VCEL) Shares Purchased by Deutsche Bank AGMay 24 at 3:38 AM | marketbeat.com5VCEL : What Analysts Are Saying About Vericel StockMay 23 at 3:15 PM | benzinga.comVericel Co. (NASDAQ:VCEL) Stock Position Cut by BNP Paribas Financial MarketsMay 23 at 3:16 AM | marketbeat.comRafferty Asset Management LLC Lowers Stake in Vericel Co. (NASDAQ:VCEL)May 22 at 4:56 AM | marketbeat.comLazard Asset Management LLC Purchases 5,923 Shares of Vericel Co. (NASDAQ:VCEL)May 22 at 4:15 AM | marketbeat.comSoleus Capital Management L.P. Purchases Shares of 80,696 Vericel Co. (NASDAQ:VCEL)May 21 at 8:13 AM | marketbeat.comVericel Co. (NASDAQ:VCEL) Holdings Raised by D. E. Shaw & Co. Inc.May 20, 2025 | marketbeat.comAmeriprise Financial Inc. Sells 124,122 Shares of Vericel Co. (NASDAQ:VCEL)May 19, 2025 | marketbeat.comVericel at BofA Securities Conference: Growth and Innovation in HealthcareMay 17, 2025 | investing.comVericel Co. (NASDAQ:VCEL) Given Consensus Rating of "Buy" by BrokeragesMay 15, 2025 | marketbeat.comStockNews.com Downgrades Vericel (NASDAQ:VCEL) to SellMay 15, 2025 | marketbeat.comNorthern Trust Corp Buys 44,397 Shares of Vericel Co. (NASDAQ:VCEL)May 13, 2025 | marketbeat.comLeerink Partnrs Has Positive Outlook of Vericel Q4 EarningsMay 13, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Issues Earnings ResultsMay 12, 2025 | marketbeat.comFirst Trust Advisors LP Lowers Stock Holdings in Vericel Co. (NASDAQ:VCEL)May 12, 2025 | marketbeat.comFrontier Capital Management Co. LLC Has $15.82 Million Stock Holdings in Vericel Co. (NASDAQ:VCEL)May 11, 2025 | marketbeat.comWhich Is a Better Investment, BioCryst Pharmaceuticals, Inc. or Vericel Corporation Stock?May 10, 2025 | aaii.comHsbc Holdings PLC Acquires New Position in Vericel Co. (NASDAQ:VCEL)May 10, 2025 | marketbeat.comVericel Corporation: Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability GuidanceMay 9, 2025 | finanznachrichten.deVericel Corp (VCEL) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...May 9, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Undervalued Stocks Wall Street Is Getting WrongBy Gabriel Osorio-Mazilli | May 12, 2025View 3 Undervalued Stocks Wall Street Is Getting WrongSavvy Investors Are Raising a Glass for Heineken StockBy Chris Markoch | May 18, 2025View Savvy Investors Are Raising a Glass for Heineken StockIs Reddit Stock a Buy, Sell, or Hold After Earnings Release?By Gabriel Osorio-Mazilli | May 5, 2025View Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?3 Boring Stocks Outperforming the Market This YearBy Ryan Hasson | April 25, 2025View 3 Boring Stocks Outperforming the Market This YearIs NIO Stock Set for a Comeback? Fundamentals Say YesBy Gabriel Osorio-Mazilli | May 19, 2025View Is NIO Stock Set for a Comeback? Fundamentals Say YesTALS, IBRX, IMVT, and VCEL Company DescriptionsImmunityBio NASDAQ:IBRX$2.53 -0.15 (-5.60%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.54 +0.01 (+0.40%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Immunovant NASDAQ:IMVT$14.46 -0.10 (-0.69%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$14.47 +0.01 (+0.07%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Talaris Therapeutics NASDAQ:TALSTalaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.Vericel NASDAQ:VCEL$40.92 -0.46 (-1.11%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$40.92 0.00 (0.00%) As of 05/23/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
